Real-world outcomes show variable visual gain despite strong anatomical response in treatment-naïve neovascular age-related macular degeneration patients, indicating efficacy of afl8.
The first 1-year real-world experience with afl8 in patients with nAMD revealed a robust anatomical response but only a variable and limited visual gain over 12 months due to a ceiling effect. Our findings confirm the fast and sustained macular drying reported from clinical trials, allowing for extended treatment intervals without compromising safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Grimaldi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: